Brief: Lava Therapeutics Announces Treatment Of First Patient In Phase 1/2A Clinical Trial Of Lava-1207
01/02/2022 11:31
Feb 1 (Reuters) - LAVA Therapeutics NV LVTX.O :
* LAVA THERAPEUTICS ANNOUNCES TREATMENT OF FIRST PATIENT IN
PHASE
1/2A CLINICAL TRIAL OF LAVA-1207 FOR METASTATIC
CASTRATION-RESISTANT PROSTATE CANCER
Source text for Eikon: ID:nGNX7GrYnh
Further company coverage: LVTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LAVA Therapeutics NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 07:29 PM
Brief: Xoma Royalty Announces Closing Of Transactions To Acquire Lava Therapeutics N.V.
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM